Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop
| Autor: | Rsw Tsang, Marina Ulanova, Michael G. Bruce, L Barreto, Andrew D. Cox |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Licensure
medicine.medical_specialty business.industry Public health 030231 tropical medicine General Medicine Disease Indigenous Clinical trial 03 medical and health sciences 0302 clinical medicine Family medicine Political science Health care Agency (sociology) medicine 030212 general & internal medicine Haemophilus influenzae serotype business |
| Zdroj: | Canada Communicable Disease Report. 43:89-95 |
| ISSN: | 1481-8531 |
| DOI: | 10.14745/ccdr.v43i05a02 |
| Popis: | Since the late 1990s there has been an emergence of Haemophilus influenzae serotype a (Hia) infections, especially in Indigenous communities in the northern regions of Canada and Alaska associated with significant morbidity and approximately a 10% mortality. A Hia vaccine could potentially prevent this disease and save the health care system millions of dollars in both acute and long-term care. On March 23-24, 2016, the National Research Council (NRC), the Public Health Agency of Canada (PHAC) and the Canadian Institutes of Health Research (CIHR) co-organized a meeting on H. influenzae serotype a (Hia) to examine the current state of disease epidemiology and a potential vaccine solution path. The meeting included representatives from academia, federal and territorial public health units, hospital laboratories, federal departments involved in Aboriginal health, advocacy organizations for Indigenous peoples and industry. Representatives from industry confirmed having the capacity and the interest to support preparation of clinical trial batches. Canadian regulatory authorities have expressed a willingness to help ensure appropriate measures are in place for licensure purposes. Furthermore, there is the capacity and interest in performing some clinical trials in Indigenous communities in both Canada and Alaska. Recommendations for next steps included: complete pre-clinical studies, improve epidemiological surveillance to better understand the extent of the disease in the rest of North America and globally, establish engagement mechanisms with national Indigenous organizations to ensure their peoples are fully involved in the process and explore funding opportunities to prepare clinical lots and undertake clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|